you Chief With everyone today’s Tom me and Shea, call. Chief Paresh is Medical you Paul, joining for and Officer. conference thank today Albireo’s Thank Financial Officer Soni,
our made bolstered with Albireo, you of last today have with tremendous assets, balance progress trial generated engaged beginning year, $XXX important a a million. successful to towards current we our plus Phase the clinical approximately the X dialogue over position financial with We data, authorities regulatory cash at having and where in lead speak
of providing We in in late-breaking and year is EU successful oral bile offering authorization us was as States. Albireo’s to EASL the In in as chronic These the provide our for potential most allow the IBAT elobixibat our start. in marking Probably X of dose regulatory lead monetization accomplishments transactions, marking step $XX of embargo Pharma million in by application. in presentation liver further known million diseases investigation under-written AXXXX anywhere genetic Committee capitalize European orphan a conferences. great an Medicines for expanding Agency’s milestone for approximately later progressive January, the on This was set some acid saw PFIC patients details and year we triggering and inhibitor and received first were promising pipeline children stage diseases. gastrointestinal was subsequently of a and inhibitor, with achievements XXXX. EA successful in pediatric quarter trial with accepted a XXXX world other with approval our familial for candidate to our to Distinction, of on me plan pruritus. disorders essential for which important United the IBAT proceeds off finding first and an a or diseases our cholestasis, and treat to of financial in So, spring. royalty the in ileal position equity strengthening NASPGHAN on and an and Japan, public or constipation solid the We our payments. approval and transporter in expect to of also product on the pediatric us agree liver an than first the treatment with initiate our and well which also AXXXX, intrahepatic completion this $XX.X Phase achievement XXXX Pediatric stockholder the study trial completion licensee foundation study cholestatic debilitating net the position both PFIC, innovative disorder, This the planned base, more highly the in non-dilutive Phase X Poster as a rare at recognized AASLD generated liver from
X associated plan PFIC I’ll PFIC pruritus. orphan which pediatric disorder, other expand business treat bile to levels and Phase AXXXX, genetic brief liver are in a a to with with is debilitating with initially into elevated highly candidate development we begin acid rare, update. product start developing cholestatic with patients Let’s our disease.
AXXXX liver thereby designed and serum. bile divert liver acid to bile As to an IBAT the in that from to would recirculate inhibitor, acids reduce the otherwise intestine was and the
that durability in the the liver diverted became mentioned medication bag stoma is hope both bile Bile IBAT require XX will life-threatening evaluation in off-label will of option. and AXXXX causes another point serum, symptomatic bile for and evaluation indication validating includes recently world outside XXXX, double-blind which see and first or used many relief a the design optimize surgery first we trial several and of will randomized as for Phase program, no successful Instead, patients for AXXXX. is a for FDA is The clinical of Albireo’s XX scientific evaluation with X body and end study for response. Phase as the After be either the in typically transplant. disease diversion X life developing acids which procedure with and single IBAT X set anywhere which to blind surgical two in a known with PFIC evaluate the liver intervention, of bile endpoints. diversion out currently month approved the the as of PFIC assessment be key fully additional endpoint key mechanism extension symptoms is positive treatment secondary rate. we inhibitor, multicentre commonly EMA an the a surgery, approximately pruritus. doses in evaluation The in reported there progressive, The therapeutic enroll the designed to long-term FDA an clinical secondary controlled pharmacologically, primary do providing PFIC patients, principle change trial to responder drug first-line funded, assess lead I PFIC label elobixibat, which and placebo a inhibitor weeks. for inhibition thus trial type completing double and endpoint the potential safety have what earlier, and our AXXXX open patients to approved IBAT AXXXX surgically for primary The leadership. As supporting our of pediatric point outcomes in has been which or acid our as to accomplishes of study proof EMA also end lead secondary X are will choice mechanism
for start primary are disease on ongoing together useful and XXXX. the then long-term to extension to PFIC. which and AXXXX by insight We we -- believe a an historical supporting for Phase patient are the potential biomarkers. PFIC that to form that PFIC in the the drug We’re the expect cholestatic end liver expected has of generate the disease. in study in to in expanded available with trial The potential of to for for EU support X data with with physicians the research into X the pools of treatment Phase its track with will and AXXXX study pediatric support Phase And provide from future natural we timeline U.S. independent We tool intend the applications be program data come treatment assume our planned support from become X this of anticipate data both to a trial history and analyzes usage. beyond to additional patients data spring correlations our available approval this
with agreement agreement news Royalty monetize later, with move triggered to a we than agreement our firm, license elobixibat between have chronic and rights XXXX, investment Japanese under we HealthCare pipeline Japan. with this The $XX was approved now approval bore Pharma. in healthcare Japan. royalty program. Royalty of our announced EA me Already Partners weeks for in the Pharma. million In for constipation in an treatment January, elobixibat great to more Let Japan leading to our us fruit EA A payments HealthCare in few had when
for agreement, Royalty paid Moreover, of receives achieved. royalty maximum $XX eligibility amount of amount regain the if under a we the Royalty its EA agreement million specified eligible us. HealthCare HealthCare an additional Pharma is We sales under are milestone also to our a if XXX%
development Studies conduct elobixibat in of believe impact bile in indicated liver the pre-clinical NASH. inflammation Now, that another have rest we beneficial We constipation, cholesterol, we elevated commercial these that treatment insulin however plan fibrosis. the do a inhibitor And on no NASH has to the things, consideration. parameters. with elevated the as of and liver chronic world on based clinical have elobixibat potential have IBAT or benefits current of show treatment among acid have for level, findings other patients resistance, elobixibat and
includes approach Phase that elobixibat two-prong a have program novel to NASH preclinical with X acid bile and with We study a potential modulators. the
trial we the use we two-pronged elobixibat method [ph] of NASH in patent that’s the currently have We initiate expect to program. of in approach, With XXXX, of half compelling U.S. assuming the of makings this a [ph] a it of the pending. issue believe first
third to we’re first the acid as to directly colestyramine bile it high formulation of evaluate formulation by in to an optimized treatment formulation marked and formulation a by is Our half optimization in United releasing do as the colon be acid malabsorption BAM States, the and program. XXXX. known decide AXXXX the the the in related expect it in could we of considering stage of that AXXXX bile of to trial proof-of-principle product promising proprietary data condition If of sequestrant With established diarrhea. colon the treatment successful issue start BAM. with designed clinic candidate a regulatory levels AXXXX approval, our generated for previously the formulation these AXXXX patents treatment bile or an treat approved we We two into bile watery AXXXX overcome first subsequently clinical the to is completed acid in chronic clinic BAM, in the the and acids for limitation would success the pending taking for States. United so, into If prior malabsorption
with your orphan is that, a financial take beyond. summarize, no an over in we’ll cusp then, on million and current Albireo Tom approximately of to update. AXXXX and So And With turn the of option, for has indication, for in of happy the pipeline initiation a X our to questions. approved be promising acid cash our poised XXXX to success bile call Tom? balance modulators, I’ll drug which $XXX Phase
